Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License...
AEGEA Medical announced today that it has completed enrollment in the Post-Ablation Cavity Evaluation Mexico (PACE MX) clinical study of women who previously underwent endometrial ablation as part of a pivotal trial of AEGEA’s Mara™ Water Vapor Ablation Treatment. The...
The Government of the province of Saskatchewan has informed treating physicians that it will grant access to SPINRAZA™ to patients living with Spinal Muscular Atrophy (SMA) Saskatchewan is the second province after the province of Quebec to grant broad access...
€4 million extension to 2017 financing agreement BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), announced today that the Management Committee of the European Investment Bank (EIB) agreed to extend the 2017 financing agreement with BiondVax by an additional €4 million....
Fight Colorectal Cancer (Fight CRC) has collaborated with Flatiron Health to develop a smartphone application for its Late-Stage, MSS-CRC Clinical Trial Finder. The first-of-its-kind app — now available for both iOS and Android — enables patients with...
Eli Lilly and Company announced results from its COAST-X Phase III clinical trial of Taltz (ixekizumab) in non-radiographic axial spondyloarthritis (nr-axSpA) in patients who had no previous disease-modifying anti-rheumatic drug (bDMARD) treatment. The drug met the...
Email
Text